Multicenter, Open-Label, Uncontrolled Study to Investigate the Efficacy and Safety of the Transdermal Contraceptive Patch Containing 0.55 mg Ethinyl Estradiol and 2.1 mg Gestodene in a 21-Day Regimen for 13 Cycles in 1650 Healthy Female Subjects.

Trial Profile

Multicenter, Open-Label, Uncontrolled Study to Investigate the Efficacy and Safety of the Transdermal Contraceptive Patch Containing 0.55 mg Ethinyl Estradiol and 2.1 mg Gestodene in a 21-Day Regimen for 13 Cycles in 1650 Healthy Female Subjects.

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Feb 2011

At a glance

  • Drugs Ethinylestradiol/gestodene (Primary)
  • Indications Pregnancy
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 14 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Jan 2010 Actual patient number changed from 1453 to 1444 as reported by ClinicalTrials.gov.
    • 16 Jan 2010 Planned end date changed from 1 Jun 2011 to 1 Dec 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top